Participant flow

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) · Source last updated 2016-11-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma who met the inclusion criteria and did not meet exclusion criteria of the study were enrolled and were evaluated for the presence of BRAF V600 mutations by collecting tumor samples or performing fresh biopsies according to local standards.

   id

   FG000

   title

   Participants With Confirmed Solid Tumors or Multiple Myeloma

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         114

      type

      No sampling or biopsy procedures done

   milestones

   1. achievements

      1. comment

         This includes all the participants who were enrolled for this study.

         group Id

         FG000

         num Subjects

         662

      type

      STARTED

   2. achievements

      1. comment

         This includes all the participants with mutation results from the sampling or biopsy procedures.

         group Id

         FG000

         num Subjects

         548

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         114

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice